靶向肺癌中的SHP2信号通路 - Suppr

Suppr

超能文献

Targeting SHP2 Signaling in Lung Cancer.

作者信息

Imbody Denis, Arce Keishla, Solanki Hitendra S, Haura Eric B, Pellini Bruna

机构信息

Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

School of Medicine, Ponce Health Sciences University, Ponce, Puerto Rico.

出版信息

J Thorac Oncol. 2024 Jan;19(1):18-24. doi: 10.1016/j.jtho.2023.08.009. Epub 2023 Aug 11.

DOI:10.1016/j.jtho.2023.08.009

PMID:37574134

Abstract

摘要

相似文献

Targeting SHP2 Signaling in Lung Cancer.靶向肺癌中的SHP2信号通路

J Thorac Oncol. 2024 Jan;19(1):18-24. doi: 10.1016/j.jtho.2023.08.009. Epub 2023 Aug 11.

Src homology phosphotyrosyl phosphatase 2 mediates cisplatin-related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.Src 同源磷酸酪氨酸磷酸酶 2 通过抑制细胞凋亡和激活 Ras/PI3K/Akt1/survivin 通路介导肺癌细胞对顺铂相关药物耐药。

Oncol Rep. 2018 Feb;39(2):611-618. doi: 10.3892/or.2017.6109. Epub 2017 Nov 24.

Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.六氯酚是一种选择性SHP2抑制剂，通过抑制RAS/MEK/ERK和PI3K/AKT信号通路来抑制KRAS突变型非小细胞肺癌细胞的增殖和转移。

Toxicol Appl Pharmacol. 2022 Apr 15;441:115988. doi: 10.1016/j.taap.2022.115988. Epub 2022 Mar 18.

Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors.ALK 和 SHP2 抑制剂联合抑制 ALK 阳性肺癌细胞生长的协同作用机制。

Sci Rep. 2023 Jun 20;13(1):10041. doi: 10.1038/s41598-023-37006-2.

Protein Tyrosine Phosphatase Non-Receptor 11 (/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).蛋白酪氨酸磷酸酶非受体 11（/ Shp2）作为非小细胞肺癌（NSCLC）中的驱动癌基因和新的治疗靶点。

Int J Mol Sci. 2023 Jun 23;24(13):10545. doi: 10.3390/ijms241310545.

JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.JC-010a，一种新型选择性 SHP2 变构抑制剂，克服了多种癌基因成瘾性肿瘤中 RTK/非 RTK 介导的耐药性。

Cancer Lett. 2024 Feb 1;582:216517. doi: 10.1016/j.canlet.2023.216517. Epub 2023 Dec 13.

SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.SHP2在多种受体酪氨酸激酶的上游和下游均发挥作用，以促进基底样和三阴性乳腺癌的发展。

Breast Cancer Res. 2016 Jan 4;18(1):2. doi: 10.1186/s13058-015-0659-z.

Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.在非小细胞肺癌球体中通过垂直抑制表皮生长因子受体（EGFR）信号传导显示出显著的协同作用，表明SOS1是EGFR突变癌症的一个治疗靶点。

Elife. 2020 Sep 8;9:e58204. doi: 10.7554/eLife.58204.

Inhibition of SHP2 as an approach to block RAS-driven cancers.抑制 SHP2 作为阻断 RAS 驱动型癌症的一种方法。

Adv Cancer Res. 2022;153:205-236. doi: 10.1016/bs.acr.2021.07.002. Epub 2021 Aug 3.

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer.PI3K 抑制可规避转移性三阴性乳腺癌对 SHP2 阻断的耐药性。

J Mammary Gland Biol Neoplasia. 2023 Jun 9;28(1):13. doi: 10.1007/s10911-023-09539-9.

引用本文的文献

Dual inhibition of GTP-bound KRAS and mTOR in lung adenocarcinoma and squamous cell carcinoma harboring KRAS G12C.对携带KRAS G12C的肺腺癌和肺鳞癌中GTP结合型KRAS和mTOR的双重抑制

Cell Commun Signal. 2025 May 11;23(1):220. doi: 10.1186/s12964-025-02187-y.

SHP2 promotes the epithelial-mesenchymal transition in triple negative breast cancer cells by regulating β-catenin.SHP2通过调节β-连环蛋白促进三阴性乳腺癌细胞的上皮-间质转化。

J Cancer Res Clin Oncol. 2025 Jan 29;151(2):55. doi: 10.1007/s00432-025-06097-x.

In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRASG12C-Mutant Non-Small Cell Lung Cancer.原位RAS：RAF结合与KRASG12C突变型非小细胞肺癌对KRASG12C抑制剂的反应相关。

Clin Cancer Res. 2025 Mar 17;31(6):1150-1162. doi: 10.1158/1078-0432.CCR-24-3714.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验